It’s Official: The World is Running Out of Antibiotics, WHO Report Confirms
This article is shared with permission from our friends at WHO.
A report, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
Most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including drug-resistant tuberculosis which kills around 250 000 people each year.
“Antimicrobial resistance is a global health emergency that will seriously jeopardize progress in modern medicine,” says Dr. Tedros Adhanom Ghebreyesus, Director-General of WHO. “There is an urgent need for more investment in research and development for antibiotic-resistant infections including TB, otherwise we will be forced back to a time when people feared common infections and risked their lives from minor surgery.”
In addition to multidrug-resistant tuberculosis, WHO has identified 12 classes of priority pathogens – some of them causing common infections such as pneumonia or urinary tract infections – that are increasingly resistant to existing antibiotics and urgently in need of new treatments.
The report identifies 51 new antibiotics and biologicals in clinical development to treat priority antibiotic-resistant pathogens, as well as tuberculosis and the sometimes deadly diarrhoeal infection Clostridium difficile.
Among all these candidate medicines, however, only 8 are classed by WHO as innovative treatments that will add value to the current antibiotic treatment arsenal.
There is a serious lack of treatment options for multidrug- and extensively drug-resistant M. tuberculosis and gram-negative pathogens, including Acinetobacter and Enterobacteriaceae (such as Klebsiella and E.coli) which can cause severe and often deadly infections that pose a particular threat in hospitals and nursing homes.
There are also very few oral antibiotics in the pipeline, yet these are essential formulations for treating infections outside hospitals or in resource-limited settings.
“Pharmaceutical companies and researchers must urgently focus on new antibiotics against certain types of extremely serious infections that can kill patients in a matter of days because we have no line of defence,” says Dr. Suzanne Hill, Director of the Department of Essential Medicines at WHO.
To counter this threat, WHO and the Drugs for Neglected Diseases Initiative (DNDi) set up the Global Antibiotic Research and Development Partnership (known as GARDP). On 4 September 2017, Germany, Luxembourg, the Netherlands, South Africa, Switzerland and the United Kingdom of Great Britain and Northern Ireland and the Wellcome Trust pledged more than €56 million for this work.
“Research for tuberculosis is seriously underfunded, with only two new antibiotics for treatment of drug-resistant tuberculosis having reached the market in over 70 years,” says Dr. Mario Raviglione, Director of the WHO Global Tuberculosis Programme. “If we are to end tuberculosis, more than US$ 800 million per year is urgently needed to fund research for new antituberculosis medicines”.
New treatments alone, however, will not be sufficient to combat the threat of antimicrobial resistance. WHO works with countries and partners to improve infection prevention and control and to foster appropriate use of existing and future antibiotics. WHO is also developing guidance for the responsible use of antibiotics in the human, animal and agricultural sectors.
Note to editors
For more information, download the following reports:
- Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis
- Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis
The clinical pipeline analysis data can be explored in an interactive way through:
A quick note from our founder
I wanted to tell you about a better and far easier way to get all your daily nutritional needs and then some into your diet...
It's so incredible, I've done the unthinkable. YES, I sold my juicer--never to juice again!
And NO I am not spending good money on outrageously expensive smoothies at those high-priced franchises or shots of wheatgrass at $5 a pop.
No this is way easier and cheaper…
In fact, each serving takes just 30 seconds to make and contains all your daily nutrition needs and more-- and at the same time, costs JUST $1.36 per serving.
You can make a glass in a snap, with water or almond milk and just a spoon or a water bottle.
Maybe best of all, each serving contains no sugar and there's no gag-reflex from the yucky taste of the dreaded green foam : )
Check out my new inexpensive, juicer-free juicing method
Latest posts by Healthy Holistic Living (see all)
- You’re Only As Happy As Your Least Happy Child - January 19, 2018
- What does the way you sit reveal about your personality? - January 19, 2018
- 6 Best Core Exercises You Can Do at Home Without Equipment - January 19, 2018